CA
BBP icon

Calton & Associates’s Virtus Biotech ETF BBP Stock Holding History

Calton & Associates’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,065
Closed -$91K – 420
2017
Q4 		$91K Buy
+2,065
New +$82.4K 0.02% 512

Other funds holding BBP

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SMG
Smart Money Group Eastland, Texas $390M AUM 21.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
FAIM
Financial Advocates Investment Management Olympia, Washington $178M AUM 21.03% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return

Calton & Associates's BBP Position: Q1 2018 in Review

Calton & Associates sold out of Virtus Biotech ETF (BBP) in Q1 2018, closing a stake of 2,065 shares — an estimated $91K sold.

Calton & Associates first reported a position in BBP in Q4 2017 and held it in 1 quarter. The position peaked at $91K in Q4 2017. 19 funds tracked by Wall St. Rank hold BBP as of Q1 2018.

  • Calton & Associates reported no remaining Virtus Biotech ETF position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 2,065 Virtus Biotech ETF shares in Q1 2018, an estimated $91K.
  • Calton & Associates first reported a position in Virtus Biotech ETF in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Virtus Biotech ETF position peaked at $91K in Q4 2017.
  • 19 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.